| Recruiting | Evaluation of Miricorilant on Liver Fat in Patients With MASLD NCT06947304 | Corcept Therapeutics | Phase 1 |
| Completed | A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants NCT06024408 | Regeneron Pharmaceuticals | Phase 1 |
| Recruiting | To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects NCT06216041 | Changchun Intellicrown Pharmaceutical Co. LTD | Phase 1 |
| Withdrawn | Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH NCT05118360 | Gannex Pharma Co., Ltd. | Phase 2 |
| Active Not Recruiting | A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfun NCT06108219 | Corcept Therapeutics | Phase 2 |
| Recruiting | Study of ADI-PEG 20 Versus Placebo in Subjects With NASH NCT05842512 | Polaris Group | Phase 2 |
| Active Not Recruiting | A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepa NCT05692492 | Guangdong Raynovent Biotech Co., Ltd | Phase 2 |
| Completed | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH NCT05591079 | Cascade Pharmaceuticals, Inc | Phase 2 |
| Completed | HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabete NCT05623189 | HighTide Biopharma Pty Ltd | Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis NCT05402371 | Hepion Pharmaceuticals, Inc. | Phase 2 |
| Completed | A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients Wit NCT05320146 | Corcept Therapeutics | — |
| Completed | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalc NCT05117489 | Corcept Therapeutics | Phase 1 |
| Completed | A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH NCT04880031 | Boston Pharmaceuticals | Phase 2 |
| Unknown | A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects NCT04913090 | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 |
| Terminated | Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic NCT04267393 | Bristol-Myers Squibb | Phase 2 |
| Completed | A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepati NCT04616014 | Oramed, Ltd. | Phase 2 |
| Completed | Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis NCT04521114 | CytoDyn, Inc. | Phase 2 |
| Terminated | Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nona NCT03823703 | Corcept Therapeutics | Phase 2 |
| Completed | Multiple Dose Safety, Tolerability, PK，PD and Food Effect Study of HEC96719 in Healthy Adult Subjects NCT04546984 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Completed | Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohe NCT04977661 | Kafrelsheikh University | Phase 4 |
| Completed | The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects NCT04194242 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Completed | Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER NCT04165343 | University of California, Davis | — |
| Recruiting | Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis NCT03572465 | Centre hospitalier de l'Université de Montréal (CHUM) | — |
| Suspended | A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR) NCT04104321 | Galmed Research and Development, Ltd. | Phase 3 |
| Completed | The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis NCT04134091 | Lipocine Inc. | Phase 2 |
| Terminated | A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis NCT04004325 | Forma Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechani NCT06037577 | ChemomAb Ltd. | Phase 1 |
| Completed | Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the NCT03392779 | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Feasibility of VIIT in Adults With NASH NCT03861819 | Duke University | N/A |
| Completed | Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis NCT02854605 | Gilead Sciences | Phase 2 |
| Completed | Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepati NCT02891408 | Gilead Sciences | Phase 1 |
| Completed | Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis NCT02856555 | Gilead Sciences | Phase 2 |
| Completed | Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function NCT02808312 | Gilead Sciences | Phase 1 |
| Completed | Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Stea NCT02781584 | Gilead Sciences | Phase 2 |
| Completed | Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS- NCT02654002 | Gilead Sciences | Phase 1 |
| Completed | Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) NCT02443116 | NGM Biopharmaceuticals, Inc | Phase 2 |
| Completed | Tesamorelin Effects on Liver Fat and Histology in HIV NCT02196831 | Massachusetts General Hospital | N/A |
| Completed | Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound NCT02044523 | Centre hospitalier de l'Université de Montréal (CHUM) | — |
| Unknown | Association of Non-alcoholic Fatty Liver Disease and Coronary Artery Disease NCT01638832 | Johann Wolfgang Goethe University Hospital | N/A |
| Completed | The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT) NCT01265498 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
| Terminated | Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH) NCT00845845 | University of Illinois at Chicago | Phase 2 |